PTC THERAPEUTICS, INC. PTCT

Latest FY: 2025 Healthcare Biotechnology
Market Price $67.39
Market Cap $5.59B
P/E Ratio 8.66
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑114.5% YoY
$1.73B
3-Yr CAGR: 35.3%
Net Income ↑287.9% YoY
$682.64M
Net Margin: 39.4%
Free Cash Flow ↑715.1% YoY
$702.34M
FCF Yield: 12.57%
EPS (Diluted) ↑264.5% YoY
$7.78
Basic: $8.58
Return on Equity Efficiency
N/A
ROA: 23.5%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (PTCT)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $82.7M $82.7M $-142.1M $-4.17 0.00% $-103.6M $-105.3M
FY 2017 $194.4M +135.0% $189.8M $-79.0M +44.4% $-2.02 +51.6% 0.00% $-10.1M $-13.2M +87.5%
FY 2018 $264.7M +36.2% $252.1M $-128.1M -62.1% $-2.75 -36.1% 0.00% $-27.6M $-34.7M -163.9%
FY 2019 $307.0M +16.0% $294.8M $-251.6M -96.4% $-4.27 -55.3% 0.00% $-98.6M $-112.4M -223.6%
FY 2020 $380.8M +24.0% $-186.6M $-438.2M -74.2% $-6.64 -55.5% 0.00% $-194.1M $-211.9M -88.5%
FY 2021 $538.6M +41.4% $-88.7M $-523.9M -19.6% $-7.43 -11.9% 0.00% $-251.3M $-279.5M -31.9%
FY 2022 $698.8M +29.7% $-121.4M $-559.0M -6.7% $-7.79 -4.8% 0.00% $-356.7M $-388.7M -39.0%
FY 2023 $937.8M +34.2% $-107.0M $-626.6M -12.1% $-8.37 -7.4% 0.00% $-158.4M $-186.9M +51.9%
FY 2024 $806.8M -14.0% $-1.7M $-363.3M +42.0% $-4.73 +43.5% 0.00% $-107.7M $-114.2M +38.9%
FY 2025 $1,730.7M +114.5% $1,214.1M $682.6M +287.9% $7.78 +264.5% 0.00% $711.2M $702.3M +715.1%
$

Valuation

Market Price $67.39
Market Cap $5.59B
Enterprise Value $5.18B
P/E Ratio 8.66
P/B Ratio N/A
FCF Yield 12.57%
Dividend Yield N/A
Shares Outstanding 82,949,300
%

Profitability & Margins

Gross Margin 70.15%
Operating Margin 50.09%
Net Margin 39.44%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) 23.55%
Asset Turnover 0.60x
Revenue 3-Yr CAGR 35.30%
🛡️

Financial Health & Liquidity

Current Ratio 2.35
Cash Ratio 1.02
Debt / Equity -2.792
Debt / Assets 0.198
Cash & Equivalents $984.65M
Total Debt $573.26M
Book Value / Share $-2.48
💧

Cash Flow Efficiency

Operating Cash Flow $711.20M
Capital Expenditures (CapEx) $8.86M
Free Cash Flow $702.34M
OCF / Revenue 41.09%
FCF / Revenue 40.58%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $7.78
EPS (Basic) $8.58
Dividends / Share N/A
Book Value / Share $-2.48
EPS YoY Growth 264.48%
🏛️

Balance Sheet (FY 2025)

Total Assets $2.90B
Total Liabilities $3.10B
Stockholders' Equity -$205.31M
Current Assets $2.27B
Current Liabilities $968.43M